Search details
1.
Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks.
Immunity
; 57(2): 287-302.e12, 2024 Feb 13.
Article
in English
| MEDLINE | ID: mdl-38354704
2.
Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients.
Cancer Immunol Immunother
; 70(10): 3015-3030, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34120214
3.
De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder.
Am J Hum Genet
; 100(2): 352-363, 2017 Feb 02.
Article
in English
| MEDLINE | ID: mdl-28132691
4.
De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder.
Am J Hum Genet
; 100(4): 689, 2017 04 06.
Article
in English
| MEDLINE | ID: mdl-28388435
5.
Sensitive bispecific chimeric T cell receptors for cancer therapy.
Res Sq
; 2024 Apr 22.
Article
in English
| MEDLINE | ID: mdl-38746248
6.
CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells.
Front Immunol
; 15: 1340619, 2024.
Article
in English
| MEDLINE | ID: mdl-38711498
7.
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
J Immunother Cancer
; 12(2)2024 Feb 07.
Article
in English
| MEDLINE | ID: mdl-38325903
8.
Synthetic HLA-independent T cell receptors for cancer immunotherapy.
Cancer Cell
; 40(4): 359-361, 2022 04 11.
Article
in English
| MEDLINE | ID: mdl-35413270
9.
Synthetic receptors for logic gated T cell recognition and function.
Curr Opin Immunol
; 74: 9-17, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34571290
10.
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model.
Cancers (Basel)
; 13(6)2021 Mar 12.
Article
in English
| MEDLINE | ID: mdl-33809167
11.
Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma.
Blood Cancer Discov
; 1(2): 130-133, 2020 09.
Article
in English
| MEDLINE | ID: mdl-34661143
12.
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
J Immunother Cancer
; 8(1)2020 01.
Article
in English
| MEDLINE | ID: mdl-32001504
13.
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
J Immunother Cancer
; 8(2)2020 11.
Article
in English
| MEDLINE | ID: mdl-33188038
14.
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.
Science
; 369(6506): 936-942, 2020 08 21.
Article
in English
| MEDLINE | ID: mdl-32820119
15.
TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features.
Front Immunol
; 9: 1962, 2018.
Article
in English
| MEDLINE | ID: mdl-30214446
16.
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Oncoimmunology
; 7(1): e1364828, 2017.
Article
in English
| MEDLINE | ID: mdl-29296515
17.
Immunotherapies in transplantation and cancer: 22nd NAT meeting/2nd NAT LabEx IGO joint meeting; 1-2 June 2017, Nantes, France.
Immunotherapy
; 9(11): 867-870, 2017 09.
Article
in English
| MEDLINE | ID: mdl-29338607
18.
Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy.
Cancer Res
; 77(24): 7083-7093, 2017 12 15.
Article
in English
| MEDLINE | ID: mdl-29212853
19.
Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer.
Nat Med
; 27(8): 1339-1341, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34385706
20.
PD-1 expression conditions T cell avidity within an antigen-specific repertoire.
Oncoimmunology
; 5(1): e1104448, 2016.
Article
in English
| MEDLINE | ID: mdl-26942093
Results
1 -
20
de 20
1
Next >
>>